Apomate may predict patient's chemotherapy response:
This article was originally published in Clinica
North American Scientific (NAS) has filed an application with the US FDA for permission to continue with studies to evaluate its nuclear imaging agent, Apomate - technetium-labelled annexin V - for assessing a patient's response to chemotherapy. Apomate, developed by NAS' subsidiary Theseus Imaging, targets phosphatidylserine, which is released during cell death. The Chatsworth, California company is currently conducting clinical trials of Apomate for imaging acute myocardial infarction and cardiac transplant rejection.